Seeking Alpha

Elan (ELN +3.8%) intends to spin off its loss-making Neotope drug-discovery unit into a separate...

Elan (ELN +3.8%) intends to spin off its loss-making Neotope drug-discovery unit into a separate publicly traded company, a move that will make Elan immediately profitable and could fuel speculation that it will be a more attractive acquisition target for Biogen (BIIB), which is the firm's partner for its Tysabri multiple sclerosis drug. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs